Case Report: Intensity-modulated radiotherapy combined with immunotherapy for intramedullary spinal cord metastases of lung adenocarcinoma.

Intramedullary spinal cord metastases (ISCMs) are rare in clinical practice and their presentation is usually an unfavorable sign with a median overall survival (mOS) of 3-4 months after diagnosis. Due to their rarity, heterogeneity and rapid progression, clinicians have few satisfactory guidelines or optimal management for ISCMs. Herein, we share a clinical experience of intensity-modulated radiotherapy (IMRT) combined with immunotherapy (IO) for ISCMs from lung adenocarcinoma (LUAD) that achieved a relatively high quality of life for 10 months, which has not been previously reported.